JPH02501264A - Modification of viable cells - Google Patents
Modification of viable cellsInfo
- Publication number
- JPH02501264A JPH02501264A JP63507367A JP50736788A JPH02501264A JP H02501264 A JPH02501264 A JP H02501264A JP 63507367 A JP63507367 A JP 63507367A JP 50736788 A JP50736788 A JP 50736788A JP H02501264 A JPH02501264 A JP H02501264A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- substance
- ultrasound
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるため要約のデータは記録されません。 (57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】 生存細胞の修飾法 本発明は物質を生存哺乳動物細胞に導入し、または物質を該細胞と融合させるた めに超音波を使用することに関する。この方法は細胞に外傷を与えるが、これら を死滅または崩壊させないものである。超音波は一般に耳で検知するのには高す ぎる周波数、一般に18 kHzから20 ME tにおける機械的振動を伴う 。[Detailed description of the invention] Modification of viable cells The present invention provides methods for introducing or fusing substances into living mammalian cells. Concerning the use of ultrasound for medical purposes. Although this method traumatizes cells, these will not die or disintegrate. Ultrasound is generally too expensive to detect with the ear. accompanied by mechanical vibrations at high frequencies, typically 18 kHz to 20 MEt. .
超音波は生存哺乳動物組織に対して診断および治療の目的で用いられている。害 を与えずに施すことができる最大強度についてW、D、ウルリッヒ(IEEE 生物医学工学に関する報告書、1974年1月、48〜51頁)により論評され ている。Ultrasound is used for diagnostic and therapeutic purposes on living mammalian tissue. harm Regarding the maximum strength that can be applied without giving Report on Biomedical Engineering, January 1974, pp. 48-51). ing.
超音波は複雑な化合働程、たとえばDNAを含めたポリマーを分解または崩解さ せるために広く用いられている。このための超音波ディスイッチグレーターが市 販されている。Ultrasound can perform complex chemical processes such as breaking down or disintegrating polymers, including DNA. It is widely used to An ultrasonic diswitch grater is available for this purpose. It's on sale.
走査超音波顕微鏡はME2からGH寥の範囲の低強度の振動を利用する。Scanning ultrasound microscopy utilizes low intensity vibrations in the ME2 to GH range.
物質を生存細胞に導入するために多種多様な方法があり、これにはリン酸カルシ ウム沈殿法およびエレクトロポレーション(algctroporatton )が含まれる0エレクトロポレーシヨンは細胞をパルヌ電場に暴露するものであ り、これにより原形質膜に細孔が形成されると推定される。これはDNAを植物 および動物双方の細胞に導入するために用いられており、他の方法では達し得な かった広範な細胞型に有効に適用されている(G、チュー(G、Cks) ら、 tVsclaic Ac1ds Re5earch、Volume15 nu mber 3,1987、p、1311〜1326)。There are a wide variety of methods for introducing substances into living cells, including calcium phosphate. precipitation method and electroporation ) involves exposing cells to a Pärnu electric field. It is presumed that this leads to the formation of pores in the plasma membrane. This converts DNA into plants. It has been used to introduce into cells of both animals and animals, and it is difficult to achieve this by other methods. has been effectively applied to a wide range of cell types (G, Cks et al. tVsclaic Ac1ds Re5earch, Volume15 nu mber 3, 1987, p. 1311-1326).
同様に細胞を融合させるためにも多種多様な方法があり、これにはウィルス、た とえばセンダイまたはHIVを用いる自然な方法、およびポリエチレングリコー ル媒介による融合またはエレクトロフュージョン(m1act−rof%ハ錦) を伴う人為的方法が含まれる。エレクトロフュージョン法は主要な2工程からな る。細胞間を密に接触させるジエレクトロフオレーシス(diglgctrop h−orgsia )、および細胞膜に細孔を生じさせ、その結果密に接触して 並置された2枚の膜を融合させる電気的な膜破壊である(2.オーニジ(K、 Oh*1ahi )、Josrxalof ImmunologicaL Me thods、100(1987)181−189)。Similarly, there are many different ways to fuse cells, including viruses, Natural methods using e.g. Sendai or HIV, and polyethylene glycol Le-mediated fusion or electrofusion (m1act-rof%hanishiki) This includes artificial methods that involve The electrofusion method consists of two main steps. Ru. dielectrophoresis (diglgctrop), which brings cells into close contact h-orgsia) and create pores in the cell membrane, resulting in close contact. It is an electrical membrane breakdown that fuses two juxtaposed membranes (2.Oniji (K, Oh*1ahi), Josrxalof ImmunologicaL Me thods, 100 (1987) 181-189).
目的とする細胞間の密な接触を達成するためには超音波力を利用することができ る。融合チャンバーの場合よりはるかに短い超音波波長が採用される。これによ って真球の鎖状の細胞が生じる(純粋に伝播性の音波において)のみでなく、定 常波の最大圧力においては細胞が濃縮される。W、M、アーノルド(W、M、 A7nold )ら、(Biochats+1cal 5ociety Tra nsactions、1 986、て赤血球またはミエローマ細胞を濃縮するた めに1,0Jllhの超音波(波長1 xi )を用いた。Ultrasonic power can be used to achieve the desired close contact between cells. Ru. Much shorter ultrasound wavelengths are employed than in the case of fusion chambers. This is it This not only results in perfectly spherical chain cells (in purely propagating sound waves), but also in constant At the maximum pressure of the standing wave, cells become concentrated. W, M, Arnold (W, M, A7nold) et al., (Biochats+1cal 5ociety Tra nsactions, 1986, to concentrate red blood cells or myeloma cells. For this purpose, 1.0 Jllh ultrasonic waves (wavelength 1 xi) were used.
本発明は、細胞に容器内で、物質の存在下または物質の添加直前に、細胞に外傷 を与f−るのに十分な超音波励起処理を施すことよりなる、物質を生存哩乳動物 細胞に導入し、または物質を該細胞と融合、させる方法を提供する。The present invention provides for traumatizing the cells in a container, in the presence of a substance, or just prior to the addition of a substance. The substance can be prepared from a living mammal by subjecting it to an ultrasonic excitation treatment sufficient to give A method for introducing a substance into a cell or fusing a substance with the cell is provided.
要約すると、懸濁液状の細胞をkHzからME t の範囲の周波数の超音波に 暴露する。これらの周波数は細胞の振動を誘発し、または細胞の近辺にキャビテ ーションを誘発する。細胞膜に生じた応力により、細胞の全破裂、細胞膜の細孔 形成、または2個以上の近接細胞の融合が生じる可能性がある。この細胞破裂期 間中に、細胞が懸濁されている溶液中の物質がこれらの細胞に取込まれる可能性 がある。In summary, cells in suspension are exposed to ultrasound at frequencies ranging from kHz to MEt. expose. These frequencies induce cell vibrations or create cavities near the cells. tion. The stress generated in the cell membrane causes total rupture of the cell and pores in the cell membrane. formation, or fusion of two or more adjacent cells. This cell rupture stage During this period, substances in the solution in which the cells are suspended may be taken up by these cells. There is.
細胞はこれらに外傷を与えるのに十分な超音波励起処理が施される。これは、細 胞が並置された物質を侵入させるのに十分な程度に変化し、一時的に損傷を受け るが、死滅または崩壊しないことを意味する。恐らく、細胞膜に短期間細孔が形 成され、これにより並置された物質が細胞に侵入しまたはこれらと融合するのが 可能となるであろう。細胞に外傷を与えるのに十分な強度の超音波を発生させる 際に若干の細胞が死滅するの、は避げられないであろう。The cells are subjected to an ultrasonic excitation treatment sufficient to traumatize them. This is a thin The vesicle is altered and temporarily damaged enough to allow the apposed material to enter. meaning that it does not die or disintegrate. Possibly, short-term pores form in the cell membrane. , which allows the juxtaposed substances to enter or fuse with the cells. It will be possible. Generate ultrasound waves strong enough to traumatize cells It is inevitable that some cells will die.
哺乳動物細胞の性質は決定的でない。細胞は好ましくは水その他の流体中に懸濁 した状態に保持されるが、あるいは支持体に付着した状態で処理されてもよい。The nature of mammalian cells is inconclusive. Cells are preferably suspended in water or other fluid It may be held in a state where it is attached to a support, or it may be processed in a state where it is attached to a support.
超音波の強度は細胞に外傷を与えるのに十分であるが、これらを永久的に損傷ま たは死滅させないように選ばれる。適切な強度は多数の因子に依存し、個々の実 験計画につき容易に経験的に決定される。超音波周波数は一般に18 kHzか ら20 MHgの範囲で選ばれる。処理時間は経験的に選ばれるが、許容できな いほどの温度上昇カヨパルス状であつそもよい。数秒から数分の全処理時間が適 切であると思われる。The intensity of ultrasound is sufficient to traumatize cells, but not permanently damage them. or are selected to avoid extinction. Appropriate strength depends on many factors and depends on individual practice. It is easily determined empirically for experimental designs. The ultrasound frequency is generally 18 kHz. and 20 MHg. Processing times are chosen empirically and are not acceptable. The temperature rises to such an extent that it stays warm. A total processing time of a few seconds to a few minutes is appropriate. It seems that it is urgent.
この方法で生存細胞に取込まれる物質には蛋白質、核酸、オリゴヌクレオチド、 DNA、脂質、およびリピドベシクルが含まれる。超音波励起処理期間中にこれ らの物質を取込んだ細胞は処理に際して生き残り、続いて複製しうる。この方法 で細胞に導入された遺伝子は発現され、遺伝性様式で娘細胞に伝達されうる。Substances taken up by living cells using this method include proteins, nucleic acids, oligonucleotides, Includes DNA, lipids, and lipid vesicles. This during the ultrasonic excitation treatment period Cells that have taken up these substances can survive the treatment and subsequently replicate. this method Genes introduced into cells can be expressed and transmitted to daughter cells in a hereditary manner.
細胞内に導入する代わりに、物質をこの方法で細胞膜に取込ませることができる 。このための物質の例には脂質、疎水性蛋白質、メンブレンレセプター、脂質ベ シクル、およびリボゾームが含まれる。さらに超音波励起処理を利用して、2個 以上の並置された同種細胞または異種細胞の融合を誘発し、単一細胞を形成する こともできる。Instead of being introduced into the cell, substances can be incorporated into the cell membrane in this way. . Examples of substances for this purpose include lipids, hydrophobic proteins, membrane receptors, and lipid bases. Includes cells, and ribosomes. Furthermore, using ultrasonic excitation treatment, two Induce fusion of more than one apposed homologous or heterologous cells to form a single cell You can also do that.
細胞′は水その他の液状媒質中に懸濁した状態に保持されることが好ましい。細 胞濃度は一般に10’〜108個/−である。物質は好ましくは超音波励起処理 時に存在するが、場合により励起処理の途中または後で、細胞が外傷を受けた状 態にある間に導入することもできる。好ましくは他方の物質の濃度も高水準に保 持すべきである。Preferably, the cells' are maintained in suspension in water or other liquid medium. Thin The cell concentration is generally between 10' and 108 cells/-. The substance is preferably treated with ultrasonic excitation present, but sometimes during or after the excitation process, the cell may be traumatized. It can also be introduced while the system is still in its current state. Preferably, the concentration of the other substance is also maintained at a high level. should be held.
後述のように、懸濁液中に細胞および他の物質双方の局所的高濃度を達成するた めに超音波その他の方法を利用することができる。As discussed below, in order to achieve high local concentrations of both cells and other substances in suspension, Ultrasound and other methods can be used for this purpose.
先行技術のエレクトロポレーション法およびエレクトロフュージョン法における 効率を改善するための既知の各種手段が本発明においても有効である。グルコー ス/CaC1,7M g Cl 、、ポリエチレングリコール、アルブミン、カ ルモデユリン、ホスファチジルセリン、グリセリルモノオレエート、コレステロ ールを含むアジュバントが細胞融合のために存在してもよい。懸濁液のpH1塩 濃度および温度はすべて効率に影響を与える因子である。細胞内へのDNAのト ランスフェクションについては、キャリヤーDNA、たとえば超音波処理したサ ケ精子DNAの存在が効率を高める場合がある。In the prior art electroporation and electrofusion methods Various known means for improving efficiency are also useful in the present invention. gluco /CaC1,7M gCl, polyethylene glycol, albumin, calcium Lumodeulin, Phosphatidylserine, Glyceryl Monooleate, Cholesterol Adjuvants containing polymers may be present for cell fusion. Suspension pH 1 salt Concentration and temperature are all factors that affect efficiency. Transfer of DNA into cells For transfection, carrier DNA, e.g. The presence of sperm DNA may increase efficiency.
細胞は容器内に保持される。その寸法および形状ならびに構成材料(音響インピ ーダンス)は、用いられる超音波処理装置との関連において選ぶ必要がある。小 屋の(6sjos)ポリスチレンバイアルまたはアルチウエル型は数個の超音波 変換器によって施すことができ、これらは容器の上刃、側方もしくは下方に配置 することができ、または容器内の懸濁液中に浸漬されるプローブを備えていても よい。あるいは懸濁液は1個または2個以上の超音波変換器を経て、制御された 様式で流動されてもよい。The cells are retained within the container. Its dimensions and shape and materials of construction (acoustic impedance) -dance) must be selected in relation to the ultrasonic processing equipment used. small The shop's (6sjos) polystyrene vial or Alchiwell type can be used with several ultrasonic waves. Can be applied by transducers, these placed on the top, side or bottom of the container or even with a probe that is immersed in suspension in a container good. Alternatively, the suspension may be passed through one or more ultrasonic transducers to a controlled It may be fluidized in a fashion.
細胞を懸濁液中の特定領域に濃縮するために超音波その他の手段(たとえば定常 波)を提供することができる。Ultrasound or other means (e.g., constant wave).
1個の超音波変換器が細胞を濃縮するために設置され、一方他のものがそれらに 周期的に外傷を与えるべく操作される。または同一の変換器を双方の目的のため に使用し、電力設定を周期的に低水準から高水準へと切換えることもできる。超 音波の周波数または周波数スペクトルの制御により、細胞の融合または物質の取 込みを最適化することができる。One ultrasound transducer is installed to concentrate the cells, while the other one concentrates on them. Manipulated to cause trauma periodically. or use the same transducer for both purposes. It can also be used to periodically switch the power setting from a low level to a high level. Hyper Controlling the frequency or frequency spectrum of sound waves allows for cell fusion or material uptake. The loading can be optimized.
以下の例は本発明を説明するものである。The following examples illustrate the invention.
ポリスチレン製ビジュー(bijos)’バイアル9cm組織培養用ペトリ皿 細胞 10%子ウシ血清を含有するDMEMK懸濁した63゜、4g8.653 マウ スミエローマ細胞。DMEMはダルベツコの改良イーグル培地である。Polystyrene bijos’ vial 9cm Petri dish for tissue culture cell 63°, 4g 8.653 mice suspended in DMEMK containing 10% calf serum Sumieloma cells. DMEM is Dulbecco's modified Eagle medium.
NA F S V 2 neo/Eca R1消化物(サザーン(S6stharnP 、)およびバーブ(Barge、)、(1982)7.MoJ。NA F S V 2 neo/Eca R1 digestate (Southern (S6stearnP ) and Barge, (1982) 7. MoJ.
Appl、Gg%gt、、 Vol 1. p、 327 )。マウスキャリヤ ーDN A : Barb/cマクス牌臓および膵臓から単離し、部分切断して 全分子量を低下させた高分子量DNA0細胞生存率に対する効果に関して3種の 振幅設定につき試験した。Appl, Gg%gt, Vol 1. p, 327). mouse carrier -DN A: Isolated from Barb/c macus spleen and pancreas, partially cut Three types of high molecular weight DNA with reduced total molecular weight regarding the effect on cell viability Amplitude settings were tested.
細胞をこれらと同じ設定で別個の3個のビジニー中において(DMEM5asl /ビジュー中に5X10’個の細胞)lO秒間psV2 neo/EcoR1消 化物20μ2およびマウスキャリヤーDNA50μtの存在下に超音波処理した 。Cells were grown in three separate cultures with these same settings (DMEM5asl psV2 neo/EcoR1 depletion for 10 seconds) sonicated in the presence of 20 μt of mouse carrier DNA and 50 μt of mouse carrier DNA. .
超音波処理後に、各ビジューの内容物を6エのベトリ皿に移し、37℃で3日間 、標準的な組織培養条件下に湿度100%、空気90%およびC0,10%の雰 囲気で培養した。After sonication, the contents of each bijou were transferred to a 6-piece vetri dish and incubated at 37°C for 3 days. , an atmosphere of 100% humidity, 90% air and 0.10% CO under standard tissue culture conditions. Cultured under ambient air.
次いで細胞を下記のとお9大型容器に移した。Cells were then transferred to 9 large containers as described below.
設定0 3x9儂ペトリ皿 設定1’ 3X9cmペトリ皿 設定3 lX9cmペトリ皿 各ペトリ皿に新鮮なりMEM+10%子ウシ血清を添加して容量10−となした 。次いで抗生物質0418を1■/wt培地の濃度になるように添加した。次い で細胞を5日間インキュベートしたのち、より大型の容器に移した。この最後の 移しかえの前にベトリ皿を検査したところ、設定30皿には多数の生存/複製中 のミエローマ細胞が認められた。設定lの皿にはより少ない生存細胞が見られ、 設定00皿には生存細胞は見られなかった。Setting 0 3x9 my petri dish Setting 1’ 3X9cm Petri dish Setting 3 lx9cm petri dish Fresh MEM + 10% calf serum was added to each Petri dish to make a volume of 10- . Antibiotic 0418 was then added to a concentration of 1/wt medium. Next Cells were incubated for 5 days and then transferred to a larger container. this last When I inspected the vetri dishes before transferring, I found that there were a large number of live/replicating birds in the set 30 dishes. Myeloma cells were observed. Fewer viable cells were found in dishes with setting l; No viable cells were found in the Set 00 dish.
従ってpsV2%−〇プラスミドDNAは超音波処理したミエローマ細胞に侵入 しく対照細胞には侵入しなかった)、これらの細胞中に遺伝性様式で組込まれた 。このプラスミドは超音波処理された細胞に抗生物質0418に対する耐性を付 与した。従って超音波処理された細胞はこの抗生物質中で生存し、これに対しプ ラスミドを受容しなかった対照細胞は生存しなかった。Therefore, psV2%-〇 plasmid DNA invades sonicated myeloma cells. did not invade control cells) and was integrated into these cells in a heritable manner. . This plasmid confers resistance to the antibiotic 0418 on sonicated cells. gave. Therefore, the sonicated cells will survive in this antibiotic, whereas the sonicated cells will survive in this antibiotic. Control cells that did not receive lasmid did not survive.
さらに2週間後にもなお細胞は上記抗生物質中で生存した。これは上記の%go 遺伝子が細胞内に遺伝性の様式で組込まれたことを示す。After an additional two weeks the cells were still viable in the antibiotics. This is the above %go Indicates that the gene has been integrated into the cell in a hereditary manner.
実施例2゜ 線維芽細胞聾へのDNAのソニフエクション(So%1fa−ソニプレプ150 超音波ディスイッチグレーターMSE リンプロCLinbro)24ウ工ル組織培養ブ′し’−)−70−・ラボラト リーズ 9cmM織培養用ペトリ皿−NUNC Pバー2線維芽細胞−レトロウィルスパッケージング系(参考:セプ:z (C gpko、 C、L、)ら、Ca1137.1053−1062.1984)。Example 2゜ Sonication of DNA to Fibroblast Deafness (So%1fa-Soniprep 150 Ultrasonic diswitch grater MSE CLinbro) 24-well tissue culture plate -70-・Laboratory leeds 9cmM petri dish for tissue culture - NUNC Pbar2 fibroblast-retrovirus packaging system (Reference: SEP:z (C gpko, C, L, et al., Ca1137.1053-1062.1984).
pzzp 5v(x) ブ、ラスミドのBαmBI部位に挿入された、ヒトN− rtLj蛋白質をコードするc D N AからなるZNR3プラスミド(前掲 )。pzzp5v(x), a human N- ZNR3 plasmid consisting of cDNA encoding the rtLj protein (see above) ).
マウスキャリヤーD A’ A : BaLb / cマウス膵臓および肝臓か ら単離し、部分切断して全分子量を低下させた高分子量DNA0 方法 Psi−2細胞をリンプロプレートのウェル内へ9×10’個/−培地(DME M−フローラボラトリーズ、10%danar子ウシ海清を含有つ70−ラボラ トリーズ)の懸濁液状で襄入した。Mouse carrier D A' A: BaLb/c mouse pancreas and liver High molecular weight DNA isolated from Method Psi-2 cells were placed in the wells of the Lympro plate at 9 x 10'/- medium (DME M-Flow Laboratories, 70-Labora containing 10% Danar Calf Sea Serum It was injected in suspension form.
実施例1の場合と同様に、MSEンニブレブ150の指数マイクロプローブの先 端をウェルの中央K、この場合は培地の表面下1關の深さに挿入した。それぞれ の場合10秒間、マイクロプローブに電力を亨えた。3v1の異なる°振幅”( MSE装置上の目盛りから読取る)の設定 生存細胞 0 8.7X10’ 1 5.4X10’ 3 1.9X10’ 実際の実験については、各設定において2個のウェルを処理した。各ウェルには 9X10’個の細胞(初期)のほかに10μ2のZNR3DNAおよび10μ2 のマウスキャリヤーDNAが含まれていた。各設定において10秒間の超音波処 理後に、各ウェルから0.2tntの細胞懸濁液を計数のために取出した。細胞 数は上記のとおりであった(すなわちこの実験においては超音波処理に際してD NAは細胞生存率を変化させなかった)。As in Example 1, the tip of the index microprobe of the MSE nib 150 The end was inserted into the center of the well, in this case one depth below the surface of the medium. Each In this case, power was applied to the microprobe for 10 seconds. 3v1 different °amplitude” ( (Read from the scale on the MSE device) Settings for viable cells 0 8.7X10' 1 5.4X10' 3 1.9X10' For the actual experiment, two wells were treated in each setup. Each well has 9X10' cells (initial) plus 10μ2 ZNR3 DNA and 10μ2 It contained mouse carrier DNA. Ultrasonic treatment for 10 seconds at each setting After treatment, 0.2 tnt of cell suspension was removed from each well for counting. cell The numbers were as above (i.e., in this experiment, D NA did not change cell viability).
残存細胞をウェルの底に付着させ、この状態でこれらを37℃で湿度100%、 9%CO2/91%空気の雰囲気内に置いた。The remaining cells were allowed to adhere to the bottom of the well, and in this state they were incubated at 37°C with 100% humidity. It was placed in an atmosphere of 9% CO2/91% air.
2日後に(超音波処理、0日目−細胞スブリツテイング、2日目)、トリプシン /EDTA溶液(フローラボラトリーズ、2−/ウェル)を用いイ細胞をウェル の底から脱離させた。After 2 days (sonication, day 0 - cell smearing, day 2), trypsin / EDTA solution (Flow Laboratories, 2-/well) was used to add cells to the wells. It was detached from the bottom.
細胞を2X10cm組織培養用ペトリ皿/ウェル(すなわちソニケーターの各設 定当たり4個のベトリ皿)に移した。Cells were placed in 2X10 cm tissue culture petri dishes/wells (i.e. in each sonicator setup). 4 pieces per plate).
新鮮な培地9−を各ペトリ皿に添加し、次いでこれらを37℃のインキュベータ ーに戻し、前記と同様にインキュベートした。ただしこの場合、培地は1!9/ 1R1のG418を含有していた。プラスミドZNP3を取込んだ細胞は、この プラスミドが実施例1のpsV2naoプラスミド中に見られるものと同一の遺 伝子を含むため、この抗生物質に対して耐性であった。188日目培地を交換し た。200日目ペトリ皿上の0418耐性Psi −2細胞のコロニーを計数し た(16個以上の細胞の群をコロニーとみなした)。Add fresh medium 9- to each Petri dish and then place them in a 37°C incubator. and incubated in the same manner as above. However, in this case, the medium is 1!9/ It contained 1R1 G418. Cells that have taken up plasmid ZNP3 have this The plasmid contains the same genes found in the psV2nao plasmid of Example 1. Because it contains the gene, it was resistant to this antibiotic. On day 188, replace the medium. Ta. On day 200, count the colonies of 0418-resistant Psi-2 cells on the Petri dish. (groups of 16 or more cells were considered colonies).
結果は下記のとおりであった。The results were as follows.
これは10’コロニ一/超音波処理生存細胞106個/プラスミドDNA10μ 2すなわち1/10’個/μ2の効率を与えた。This is 10' colony/106 sonicated viable cells/10μ plasmid DNA. 2, that is, 1/10' pieces/μ2.
最大効率を達成するためには、異なる細胞型は異なるソニケーター設定および異 なるアジ五パントを必要とするであろう。To achieve maximum efficiency, different cell types require different sonicator settings and It would require five punts.
手続補正書(ji力 平成 2年 2月 tωd 1、事件の表示 PCT/GB88100738 2、発明の名称 生存細胞の修飾法 3、補正をする者 事件との関係 特許出願人 住所 名 称 アマ−ジャム・インターナショナル−ピーエルシー4、代理人 住所 東京都千代田区大手町二丁目2番1号新大手町ビル 206区 5、補正命令の日付 平成 2年 1月30日 0腿旧)6、補正の対象 タイプ印書により浄書した明細書及び請求の範囲の翻訳文国際調査報告 l1llyyB@sal Aa1++n、m、 ?CTtGB a810073 8SA 24184Procedural amendment (ji force) February 1990 tωd 1.Display of the incident PCT/GB88100738 2. Name of the invention Modification of viable cells 3. Person who makes corrections Relationship to the incident: Patent applicant address Name: AmarJam International-PLC 4, Agent Address: Shin-Otemachi Building, 206-ku, 2-2-1 Otemachi, Chiyoda-ku, Tokyo 5. Date of amendment order: January 30, 1990 (old) 6. Subject of amendment Translated international search report of the specification and claims, typewritten l1llyyB@sal Aa1++n, m,? CTtGB a810073 8SA 24184
Claims (8)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8721015 | 1987-09-07 | ||
GB878721015A GB8721015D0 (en) | 1987-09-07 | 1987-09-07 | Modifying living cells |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH02501264A true JPH02501264A (en) | 1990-05-10 |
Family
ID=10623396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63507367A Pending JPH02501264A (en) | 1987-09-07 | 1988-09-07 | Modification of viable cells |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0333799A1 (en) |
JP (1) | JPH02501264A (en) |
GB (1) | GB8721015D0 (en) |
WO (1) | WO1989002464A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK168302B1 (en) * | 1989-06-29 | 1994-03-07 | Danisco | Method of introducing molecules, especially genetic material into plant cells |
KR960700740A (en) * | 1993-03-23 | 1996-02-24 | 라차아드 엘 콘 | METHOD AND APPARATUS FOR ENCAPSULATION OF BIOLOGIC ALLY-ACTIVE SUBSTANCES IN CELLS |
US6074605A (en) * | 1995-03-10 | 2000-06-13 | Entremed, Inc. | Flow electroporation chamber and method |
US6773669B1 (en) | 1995-03-10 | 2004-08-10 | Maxcyte, Inc. | Flow electroporation chamber and method |
US5720921A (en) * | 1995-03-10 | 1998-02-24 | Entremed, Inc. | Flow electroporation chamber and method |
JP2001507207A (en) * | 1996-05-01 | 2001-06-05 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | Methods for delivering compounds to cells |
DE19834612A1 (en) * | 1998-07-31 | 2000-02-24 | Dornier Medtech Holding Int Gmbh | Method for intracellular transfer of oligonucleotides and device for carrying out the same |
JP2003533974A (en) * | 1999-12-23 | 2003-11-18 | ドルニエル メドテック システムズ ゲーエムベーハー | Equipment for introducing molecules into cells |
DE19962904A1 (en) * | 1999-12-23 | 2001-08-09 | Dornier Medizintechnik | Apparatus continuously introducing molecules into cells, avoiding their total disruption, focuses controlled acoustic pulses at axis of duct passing carrier fluid |
US7029916B2 (en) | 2001-02-21 | 2006-04-18 | Maxcyte, Inc. | Apparatus and method for flow electroporation of biological samples |
AU2002320348B2 (en) | 2001-07-10 | 2007-07-19 | Sonogene, Llc | Enhancement of transfection of DNA into the liver |
US7141425B2 (en) | 2001-08-22 | 2006-11-28 | Maxcyte, Inc. | Apparatus and method for electroporation of biological samples |
DE10223196B4 (en) * | 2002-05-24 | 2004-05-13 | Dornier Medtech Systems Gmbh | Method and device for transferring molecules into cells |
CA2565316C (en) | 2004-05-12 | 2017-05-30 | Maxcyte, Inc. | Methods and devices related to a regulated flow electroporation chamber |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3505161A1 (en) * | 1985-02-15 | 1986-08-21 | GCA Corp., Bedford, Mass. | Process and apparatus for electrofusion with the aid of sound waves |
-
1987
- 1987-09-07 GB GB878721015A patent/GB8721015D0/en active Pending
-
1988
- 1988-09-07 JP JP63507367A patent/JPH02501264A/en active Pending
- 1988-09-07 EP EP88907755A patent/EP0333799A1/en not_active Withdrawn
- 1988-09-07 WO PCT/GB1988/000738 patent/WO1989002464A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1989002464A1 (en) | 1989-03-23 |
GB8721015D0 (en) | 1987-10-14 |
EP0333799A1 (en) | 1989-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK168302B1 (en) | Method of introducing molecules, especially genetic material into plant cells | |
Wu et al. | Interspecies chimerism with mammalian pluripotent stem cells | |
JPH02501264A (en) | Modification of viable cells | |
McGrath et al. | Nuclear transplantation in the mouse embryo by microsurgery and cell fusion | |
CN100448991C (en) | Methods for cloning mammals using reprogrammer donor chromation or doner cells | |
AU2017305948B2 (en) | Internally fixed lipid vesicle | |
Ogura et al. | Behaviour of hamster and mouse round spermatid nuclei incorporated into mature oocytes by electrofusion | |
Roh et al. | In vitro development of green fluorescent protein (GFP) transgenic bovine embryos after nuclear transfer using different cell cycles and passages of fetal fibroblasts | |
US20200165569A1 (en) | Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure | |
FR2609045A1 (en) | METHOD FOR TRANSPLANTING A CORE OF A DONOR CATTLE EMBRYO IN A RECOVERY OVOCYTE, AND BOVINE EMBRYO PRODUCED THEREBY | |
JPH03502043A (en) | Method and apparatus for cell poration and cell fusion by high frequency electrical pulses | |
JPH03503718A (en) | Modified hepatocytes and their uses | |
Sato et al. | Recent advances and future perspectives of in vivo targeted delivery of genome-editing reagents to germ cells, embryos, and fetuses in mice | |
Kono et al. | Effects of induction current and other factors on large‐scale electrofusion for pronuclear transplantation of mouse eggs | |
JP5145553B2 (en) | EndoGalC-hDAF double transgenic pig | |
EP1792537A1 (en) | Method of constructing clone mammal | |
RU2201961C2 (en) | Method for obtaining protein due to using translation system of mitochondria | |
Shenoy | Animal biotechnology | |
CN106267409B (en) | AIDS biological therapy reactor | |
WO1991013977A1 (en) | Process for the artificial stimulation of cells and ovocyte culture device | |
Popova et al. | Perspectives in Genome-Editing Techniques for Livestock | |
CN116970590B (en) | Super mini-gene editor smaller than 380 amino acids and application thereof | |
Rakotondrafara et al. | Preparation and electroporation of oat protoplasts from cell suspension culture | |
James et al. | DNA-mediated gene transfer into mammalian cells | |
WO2001030970A2 (en) | Improved protocol for activation of oocytes |